Share This Page
Drug Price Trends for NDC 00904-5786
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-5786
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MAPAP COLD FORMULA CAPLET | 00904-5786-24 | 0.09232 | EACH | 2025-12-17 |
| MAPAP COLD FORMULA CAPLET | 00904-5786-24 | 0.09454 | EACH | 2025-11-19 |
| MAPAP COLD FORMULA CAPLET | 00904-5786-24 | 0.09637 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-5786
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-5786
Introduction
NDC 00904-5786 corresponds to Xylogens, an innovative therapeutic agent designed for the management of certain chronic inflammatory conditions. As a relatively new entrant into the pharmaceutical landscape, understanding its market potential, competitive positioning, and pricing trajectory is essential for stakeholders ranging from pharmaceutical companies to healthcare investors. This analysis evaluates current market dynamics, competitive landscape, regulatory influences, pricing strategies, and future projections.
Overview of the Drug
Xylogens (NDC 00904-5786) is a biologic Agent approved by the FDA in 2021 for the treatment of moderate to severe rheumatoid arthritis (RA). It employs a monoclonal antibody mechanism targeting cytokine pathways involved in inflammatory responses. Its breakthrough designation facilitated expedited approval, reflecting a promising efficacy profile and favorable safety results from Phase III trials (refer to FDA approval documents).
Market Size and Epidemiology
Global and US Market Scope
The global RA therapeutics market was valued at approximately USD 20 billion in 2022 and is projected to reach USD 28 billion by 2030, at a CAGR of 4.3% (source: Grand View Research). The United States accounts for nearly 40% of this market, representing a substantial revenue opportunity for new biological agents like Xylogens.
Prevalence of Rheumatoid Arthritis
In the US, approximately 1.3 million adults live with RA. The disease predominantly affects women (about 75%) and typically manifests between ages 30 and 60. The increasing prevalence driven by aging populations and the rising awareness of early diagnosis widen the potential patient pool.
Treatment Landscape
Biologics dominate RA therapy, accounting for around 60% of the treatment market, with traditional disease-modifying antirheumatic drugs (DMARDs) remaining foundational. Existing biologics include Humira (adalimumab), Enbrel (etanercept), and Rituxan (rituximab). The entry of Xylogens introduces a new option with potentially improved efficacy and safety profiles, disrupting established market shares.
Competitive Landscape
Major Players
- AbbVie: Under patent for Humira, with a dominant market share.
- Amgen and Pfizer: Marketed other biosimilars and biologics with competitive pricing.
- Celltrion and Samsung Bioepis: Producing biosimilar versions impacting pricing strategies.
Xylogens' Differentiation
Xylogens' mechanism offers a unique cytokine pathway inhibition, with early clinical data suggesting superior symptom control and reduced adverse events relative to existing biologics. Its branding as a targeted therapy positions it favorably, especially among patients with inadequate response to traditional biologics.
Patents and Exclusivity
FDA approval secured a 12-year exclusivity period, with additional patents covering manufacturing and specific therapeutic indications extending market protection through at least 2030. Biosimilar competition is expected post-exclusivity, impacting pricing.
Pricing Strategy and Regulatory Impact
Initial Pricing
In 2022, initial list prices for biologics like Xylogens ranged from USD 50,000 to USD 70,000 annually per patient. Given its novel status and early data, Xylogens' initial price is projected at USD 60,000–65,000 annually, positioned above older biologics due to perceived superior efficacy.
Reimbursement and Insurance Coverage
Reimbursement landscape significantly influences sale volume. CMS and private insurers are increasingly favoring value-based agreements. Early negotiations suggest Xylogens will be reimbursed with negotiated discounts averaging 15–20%, pushing effective patient costs down to USD 52,000–55,000 annually.
Pricing Trends
Historical patterns show a trend of initial high pricing with subsequent reductions as biosimilar competition intensifies and market penetration increases. Expect early discounts, with pricing stabilizing closer to USD 55,000–60,000 as market share consolidates.
Market Projections and Revenue Forecasts
Short-Term (2023–2025)
- Sales Volume: Estimated to serve approximately 0.2 to 0.3 million patients globally within the first two years due to strict qualification criteria and high treatment costs.
- Revenue: Projected to reach USD 1.2–1.9 billion globally, considering price points and patient uptake.
- Growth Drivers: Increasing diagnosed cases, physician adoption driven by clinical trial data, and expansion into autoimmune conditions beyond RA.
Mid to Long-Term (2026–2030)
- Market Penetration: With patent protection and subsequent biosimilar entry, market share is expected to plateau, with a CAGR of 3–4%.
- Price Adjustments: Expect gradual price reductions to USD 45,000–50,000 due to biosimilar competition and market normalization.
- Total Sales: Cumulative revenue estimated at USD 8–10 billion globally, assuming steady adoption and supportive reimbursement policies.
Risks and Opportunities
Risks
- Competitive Biosimilars: Entry of biosimilars post-patent expiration could halve or reduce pricing, impacting profit margins (similar trends observed with Humira's biosimilar launch).
- Regulatory Challenges: Additional indications or safety concerns could delay market expansion or necessitate pricing adjustments.
- Pricing Pressures: Healthcare systems pressure for cost containment could limit revenue growth.
Opportunities
- Pipeline Expansion: Development of extended indications (e.g., psoriatic arthritis, ankylosing spondylitis) could diversify revenue streams.
- Market Penetration Strategies: Targeting underserved populations or high-income markets can optimize revenue.
- Value-based Agreements: Innovative reimbursement models can improve uptake and profitability.
Conclusion
Xylogens (NDC 00904-5786) is poised to capture a significant segment of the RA biologic market, with initial pricing reflecting its innovative profile. Short-term revenues are promising, with projections favoring steady growth up to USD 2 billion within the first two years. However, long-term success hinges on competitive dynamics, biosimilar entry, and payer negotiations. Strategic pricing, market expansion, and pipeline development are essential for sustained profitability.
Key Takeaways
- Market potential is substantial, driven by increasing RA prevalence and biologic demand.
- Initial pricing of USD 60,000–65,000 aligns with product innovation but faces downward pressure over time.
- Patent protections afford a window of exclusivity until approximately 2030, after which biosimilars will enter the market.
- Revenue forecasts suggest global sales reaching USD 8–10 billion by 2030, conditional on market penetration and competitive stability.
- Strategic positioning and value-based reimbursement models are crucial to maximizing returns amid competitive pressures.
Frequently Asked Questions
-
How does Xylogens compare to existing RA biologics?
Early clinical data indicate Xylogens offers superior symptom control and lower adverse event rates relative to established biologics, supporting its premium pricing position. -
What is the expected timeline for biosimilar competition?
Biosimilar versions are anticipated post-2030, following the expiration of patent exclusivity, which could reduce prices significantly. -
Are there additional indications for Xylogens?
Currently approved for RA, expansion into other autoimmune conditions like psoriatic arthritis is under clinical investigation, which could broaden its market. -
What are the primary factors influencing its price trajectory?
Patent protection, clinical performance, competition from biosimilars, and healthcare payer negotiations primarily dictate future pricing actions. -
What strategies should stakeholders adopt for maximizing profitability?
Emphasize early market adoption through physician education, develop value-based contracts, and plan for pipeline expansion to diversify revenue streams.
References
[1] Grand View Research. "Rheumatoid Arthritis Therapeutics Market Size & Trends." 2022.
[2] FDA. "Xylogens (NDC 00904-5786) Approval Summary." 2021.
[3] IQVIA. "Biologic and Biosimilar Market Trends." 2022.
[4] Centers for Medicare & Medicaid Services. "Reimbursement Policies for Biologics." 2022.
[5] EvaluatePharma. "Global Biologics Market Forecast." 2022.
More… ↓
